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2586diagnosis may have serious consequences. The example of epsilon
wave reported in MOGE(S) paper was to highlight one of the
most speciﬁc markers (and a major diagnostic criterion) of the
disease (2).
Finally, the biventricular and predominantly left ventricular vari-
ants (5) as well as the less speciﬁc genetic basis of the ARVC/D
cannot be ignored. For example, ARVC/D-related desmosome gene
defects are also known to be associated with dilated cardiomyopathy
(6) and dilated cardiomyopathy–related genes such as LMNA
may also result in ARVC/D (7). Because MOGE(S) descriptors
are ﬂexible, it is rather simple to provide comprehensive informa-
tion such as MA(m43)þD(AVB) OHGADEG-LMNA[p. Lys117Arg]þ
DSC2[p.Ala596Val] SA-I, where both LMNA and PKP2 variants could
contribute to the phenotype, one to the dilated cardiomyopathy
with atro-ventricular block [LMNA p.(Lys117Arg)] and one of still
unknown pathogenicity ([DSC2 p.[Ala596Val], http://www.
arvcdatabase.info/) to the ARVC/D traits.
Taking the best from the past and approaching the future with
pragmatism would inﬂuence the quest for the development of
disease-speciﬁc, gene-based strategies for management as more
data become available to public databases. If not with MOGE(S), it
could be with any other novel system. However, any new nosology
system would not be able to ignore the consolidated proposal put
forth by the MOGE(S) nomenclature (2).Eloisa Arbustini, MD
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1744–52.Bleeding After PCI,
Vascular Access, and
Falsiﬁcation Endpoints in
Observational StudiesWe read with interest the article by Wimmer et al. (1). They
propose the use of an unexpected ﬁnding in an observational
study (that is unlikely to be causally related to the intervention
being studied) to highlight the presence of residual confound-
ing. Their strategy assumes that residual confounding accounts
for these unexpected, noncausal ﬁndings, even despite the
application of advanced and complex statistical methods to
control for confounding. However, the discovery of unexpected
results in observational studies may have other explanations
and, consequently, potentially useful applications, such as:
the search for possible alternative causal explanations, the
generation of new hypotheses, and the design of further studies
to evaluate these unexpected ﬁndings. These applications may
be useful to improve our understanding of disease pathophysi-
ology, expand the frontiers of knowledge, and ultimately
improve patient care.
From this point of view, in the present case (1), there could be
an alternative explanation for the increased bleeding rate not
apparently related to vascular access associated with femoral
percutaneous intervention (PCI); for example, the hemorrhagic
transformation of clinically unapparent embolic infarctions in
thoracoabdominal solid organs, viscera and soft tissues subsidiary
of the aortic arch, and the thoracoabdominal descending aorta.
The uneven distribution of these events according to the inter-
vention under study (femoral versus radial vascular access PCI)
could be justiﬁed by the higher probability of catheter contact
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2587with the endothelial aortic surface when using the femoral
approach (a greater length of aorta is exposed to contact with
the catheter from femoral access than from radial access).
Furthermore, the arch and descending aorta compared with the
ascending aorta are the most common locations for complex
atherosclerotic plaques responsible for embolic phenomena (2).
Moreover, antiplatelet and anticoagulant regimens may increase
the risk of hemorrhagic transformation of unapparent embolic
events and favor their clinical presentation as hemorrhagic
events. These aspects may justify the design of a speciﬁc trial
using imaging pre/post studies to assess the incidence of thor-
acoabdominal embolic events during femoral versus radial
vascular access in PCI.
Finally, some methodological aspects should be pointed out.
First, bleeding outcomes in the study by Wimmer et al. (1)
cannot be considered rare events. Falsiﬁcation hypothesis has
been proposed to validate the identiﬁcation of rare adverse ef-
fects from population data, deﬁned as those occurring in <1 per
1,000 subjects (3). Second, the authors propose a single hy-
pothesis to falsify rather than several as recommended. Falsi-
ﬁcation hypothesis should be operationalized by testing
multiple implausible pre-speciﬁed hypotheses with the same
methods applied in the primary analysis. When many false
relationships are present, caution is warranted in the interpre-
tation of study ﬁndings. Finally, the mere absence of evidence
together with a low biological plausibility according to the state
of mechanistic knowledge at that time (or even less, the opinion
of experts) do not seem enough before proposing nonaccess
bleeding as a falsiﬁcation endpoint. There is a need to positively
demonstrate from properly designed studies that such an
observed effect is unlikely to be true. Otherwise, the generation
of knowledge outside the box and scientiﬁc progress may be
halted.
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Access, and Falsiﬁcation
Endpoints in Observational StudiesWe appreciate the interest and perspective of Dr. Valencia-Serrano
and colleagues on our exploration of the use of falsiﬁcation end-
points as a method of exploring the potential for residual con-
founding in observational comparative effectiveness studies (1). We
believe that such endpoints, akin to negative controls in experi-
mental methods, are an underutilized tool in the cardiovascular
data. We have used the examination of nonaccess site bleeding in
comparing transradial and transfemoral access in percutaneous
coronary intervention (PCI) as a simple illustrative example of how
such a method might be used in practice.
The utility of any falsiﬁcation endpoint rests on the assump-
tion that the treatments being compared should not differ with
respect to their inﬂuence on these endpoints. In this case, the
assumption is that the route of access for PCI, whether trans-
radial or transfemoral, should not inﬂuence the rate of nonaccess
site bleeding in a causal manner. Dr. Valencia-Serrano and
colleagues propose that the differences observed in the falsiﬁ-
cation endpoint in our analysis may, in fact, be due to a causal
relationship between the site of arterial access and nonaccess site
bleeding, mediated through the “hemorrhagic transformation of
clinically unapparent embolic infarctions” related to catheter
contact with the aorta during transfemoral procedures. Judging
the plausibility of potential biological explanations such as these,
versus the perhaps more banal explanation that the study suffers
from residual confounding, will most often require both clinical
subject matter expertise and an understanding of the limitations
of the methods used for statistical adjustment. In this particular
example, however, we beneﬁt from the existence of a large
randomized trial of transradial and transfemoral PCI in the ST-
segment elevation myocardial infarction population showing no
difference in nonaccess site bleeding (2), which serves as vali-
dation of this falsiﬁcation endpoint. More often, however, such a
randomized study will not exist to validate other potentially
useful endpoints. In the absence of such a study, we ﬁnd the
suggestion that investigators “positively demonstrate from
properly designed studies that such an observed effect [on the
falsiﬁcation endpoint] is unlikely to be true” leads to an ines-
capable tautology: a falsiﬁcation endpoint cannot be validated by
the very study it seeks to validate.
Finally, falsiﬁcation hypotheses and endpoints need not be
limited to studies examining rare events. Although the use of
multiple such endpoints may provide stronger evidence for or
against the likelihood of residual confounding, we do not believe
that it is simply a case of “more being better.” As these methods are
increasingly utilized by the research community, we will undoubt-
edly learn more about their merits and limitations. We are hopeful
that our brief investigation will promote further examination and
innovation in observational research methods through the use of
these and other techniques.
